Drugs / Napazimone
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04643249 | Nov → Dec 2020 | mitochondrial disease | Abliva AB | Completed | No outcome recorded |
| Phase 1 | NCT03888716 | Mar 2019 → Mar 2021 | MELAS syndrome, mitochondrial respiratory chain complex deficiency, pure mitochondrial myopathy | Abliva AB | Completed | No outcome recorded |
| Phase 1 | NCT03056209 | Jun 2017 → Apr 2018 | MELAS syndrome, mitochondrial respiratory chain complex deficiency | Yungjin Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07514338 | Jun 2026 → Mar 2029 expected | mitochondrial disease | Pharming Technologies B.V. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05650229 | Dec 2022 → Oct 2027 expected | mitochondrial disease | Pharming Technologies B.V. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Napazimone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07514338 ↗ |
| Known as | KL1333 | “Product: KL1333 (international nonproprietary name: napazimone)” NCT07514338 ↗ |
| Modality | Small molecule | — CHEMBL4594430 ↗ |
| Route | Oral | “oral administration, single dose, 25 mg 1 tab” NCT03056209 ↗ |